Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
The CTMX news page on Stock Titan aggregates recent coverage and official announcements related to CytomX Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company listed on the Nasdaq Global Select Market. CytomX reports that it is developing novel, conditionally activated, masked biologics based on its PROBODY® therapeutic platform, with a focus on cancer indications such as advanced colorectal cancer and advanced melanoma.
Visitors to this page can review news items that describe the progress of CytomX’s clinical programs, including updates on varsetatug masetecan (Varseta-M, formerly CX-2051), a masked EpCAM-directed antibody-drug conjugate with a topoisomerase-1 inhibitor payload, and CX-801, a masked interferon alpha-2b PROBODY® cytokine. Company press releases have discussed Phase 1 dose escalation and expansion activities, translational biomarker data, and plans for potential later-stage development in colorectal cancer and melanoma.
In addition to pipeline updates, CytomX news often includes financial results, business updates, and information about investor conference presentations. These items provide context on the company’s operating priorities, cash position, and interactions with the investment community. News releases also highlight research and collaboration activities involving its PROBODY® platform, such as work on T-cell engagers and cytokine-based approaches in partnership with other biopharmaceutical companies.
By following CTMX news, investors and researchers can monitor how CytomX describes the evolution of its PROBODY® technology, its clinical data disclosures, and its collaborations with partners including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. This page offers a centralized view of publicly released information that may be relevant to understanding the company’s development-stage oncology pipeline and corporate activities.
CytomX Therapeutics (Nasdaq: CTMX) announced on January 15, 2021, the granting of stock options to two new employees for a total of 98,000 shares at an exercise price of $7.93, which reflects the closing price on that date. This grant is part of the 2019 Employment Inducement Incentive Plan, approved by the board in August 2020, to attract new talent to the company. CytomX is focused on developing innovative Probody therapeutics for cancer treatment, emphasizing reduced toxicity and increased effectiveness.
CytomX Therapeutics (Nasdaq: CTMX) has announced that its CEO, Sean McCarthy, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 11:40 a.m. ET. Additionally, the company will participate in a pre-recorded presentation through the SternIR Virtual Corporate Access Event from January 11-14, 2021. Webcasts will be available on CytomX’s website, with archived replays accessible for 90 days post-conference. CytomX focuses on developing innovative Probody therapeutics for cancer, partnering with major pharmaceutical companies.
CytomX Therapeutics (Nasdaq: CTMX) has appointed Mani Mohindru, PhD, to its board of directors. Dr. Mohindru, an experienced biotech executive, brings a strong background in finance and corporate strategy, previously serving as CEO of CereXis and CFO at Cara Therapeutics. Her expertise is expected to accelerate the development of CytomX's clinical pipeline, particularly its innovative Probody technology, aimed at creating selective cancer therapies. This leadership change comes as CytomX prepares for multiple critical data releases in 2021.
CytomX Therapeutics (Nasdaq: CTMX) is set to present two posters at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) from December 8-11. The presentations will focus on the clinical activity of CX-2009, a Probody drug conjugate, and its potential in treating advanced breast cancers. Notably, the data highlights the efficacy of CX-2009 alone and in combination with pacmilimab in HER2-non amplified breast cancer. The presentations occur on December 9 at 9:00 AM ET, showcasing CytomX's commitment to innovative cancer treatments.
CytomX Therapeutics (Nasdaq: CTMX) announced that Sean McCarthy, D.Phil., CEO, will participate in two virtual healthcare conferences this November. The Jefferies Virtual London Healthcare Conference is scheduled for November 18, 2020, at 10:15 a.m. ET. Additionally, the 32nd Annual Piper Sandler Virtual Healthcare Conference will occur on November 30, 2020, with a fireside chat available for on-demand viewing starting November 23, 2020, at 10:00 a.m. ET. Webcasts can be accessed on CytomX’s website with archived replays available for 90 days.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) reported its third quarter 2020 financial results, showing revenue of $17.8 million, a 66% increase from the same period in 2019. The company highlighted advancements in its clinical pipeline, including five Probody programs in the clinic, with four in Phase 2 studies. CX-2009 and CX-2029 are among the candidates being developed with initial data anticipated in late 2021. As of September 30, CytomX had $321.1 million in cash and equivalents, reflecting strong financial health.
CytomX Therapeutics (Nasdaq: CTMX) announced the initiation of a Phase 2 expansion study for CX-2029, a Probody drug conjugate targeting CD71, an important cancer target. This study will include various cancer types and is expected to enroll around 25 patients per cohort, focusing on overall response rate (ORR) and safety. The collaboration with AbbVie allows CytomX to earn up to $390 million in milestone payments. Initial data from the study is anticipated in late 2021, further showcasing CytomX's innovative approach to oncology.
CytomX Therapeutics (Nasdaq: CTMX) will announce its second quarter 2020 financial results on November 5, 2020, after U.S. market close. A teleconference will be held at 5:00 p.m. ET with a live audio webcast available on its website. CytomX focuses on developing investigational antibody therapeutics through its Probody technology, which aims to improve the efficacy and safety of cancer treatments. The company has established collaborations with major pharmaceutical entities to develop a pipeline of innovative therapeutics targeting difficult cancers.
CytomX Therapeutics (NASDAQ:CTMX) announces the retirement of W. Michael Kavanaugh, M.D., its Chief Scientific Officer, effective December 1, 2020. He will continue as an advisor on the Scientific Advisory Board. Marcia P. Belvin, Ph.D., is promoted to Senior Vice President, Head of Research, bringing nearly 20 years of oncology experience. CytomX focuses on developing Probody therapeutics, which selectively target tumors while minimizing toxicity to healthy tissues. The company's pipeline includes innovative candidates like CX-2009 and CX-2029, aimed at previously undruggable cancer targets.
CytomX Therapeutics (NASDAQ: CTMX) announced the granting of stock options to nine new employees on September 15, 2020. A total of 211,000 shares were issued at an exercise price of $7.22, equal to the closing price on that date. This action is part of the Company's 2019 Employment Inducement Incentive Plan, aimed at attracting talent. CytomX is a clinical-stage biopharmaceutical company focused on oncology, utilizing its Probody technology to develop innovative cancer treatments, partnering with major industry players like AbbVie and Bristol Myers Squibb.